# Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment

> **NCT07285941** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer
- HER2

## Interventions

- **DRUG:** RC48 + Carboplatin

## Key facts

- **NCT ID:** NCT07285941
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-04
- **Primary completion:** 2027-01-04
- **Final completion:** 2028-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285941, "Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07285941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*